Day: May 10, 2021

ACTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) — Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2021. The Company’s revenue for the quarter ended March 31, 2021 was $5.7 million versus $7.5 million for the quarter ended March 31, 2020, a decrease of 24%. Net income for the quarter ended March 31, 2021 was $0.1 million or $0.01 per diluted share, versus net loss of $0.2 million or ($0.03) per diluted share, for the comparable period last year, an increase of $0.04 per diluted share. Raymond C. Kubacki, Chairman and Chief Executive Officer, stated: “We continued to see improvement in total revenues, month-to-month and quarter-to-quarter, since the COVID-19 shutdown hit full force in April last year....

SOLANA BEACH, Calif., May 10, 2021 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced a partnership with San Diego-based D&K Engineering for the continued development of a robotic system for use in both the MRI Suite and the Operating Room. “This relationship highlights two important parts of the ClearPoint vision and strategy,” commented Joe Burnett, President and CEO at ClearPoint Neuro. “First, we must not only make functional neurosurgery procedures shorter and more consistent across our clinical sites, but we must make the Neurosurgeon’s time with their patients more productive. By automating specific parts of the planning and navigation during the procedure, we can help the surgical team to...

– 58 subjects continue in the open-label extension study for TransCon PTH – COPENHAGEN, Denmark, May 10, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create product candidates that address unmet medical needs, today announced preliminary 58-week results from the continuing open-label extension (OLE) portion of the PaTH Forward Trial, a global phase 2 trial evaluating the safety, tolerability, and efficacy of its investigational product candidate TransCon PTH in adult subjects with hypoparathyroidism (HP). “Today we announced results which demonstrated, after one year of treatment, that TransCon PTH was well-tolerated at all doses and provided durable benefit in adults with HP. Data from these subjects provided evidence suggesting they...

TORONTO, May 10, 2021 (GLOBE NEWSWIRE) — Allied Properties REIT (TSX:AP.UN) (“Allied”) announced today the results of matters voted on at its annual and special meeting of unitholders held on May 10, 2021 (the “Meeting”). The voting results for each of the matters presented at the Meeting are outlined below. There were 83,245 unitholders represented in person or by proxy at the Meeting holding 104,946,897 units, representing 82.47% of Allied’s total issued and outstanding units. 1.     Amendments to the Declaration of Trust The resolution authorizing amendments to Allied’s amended and restated declaration of trust were approved by a majority of votes cast by unitholders who voted in respect of the resolution present or represented by proxy at the Meeting. Management received proxies in respect of the amendments to the amended and...

CANTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by Organogenesis Holdings Inc. (Nasdaq: ORGO), please note that in the third bullet of the First Quarter 2021 Financial Results Summary, the net revenue from the sale of non-PuraPly products was $61.2 million, not $32.0 million. The corrected release follows: Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the three months ended March 31, 2021. First Quarter 2021 Financial Results Summary:Net revenue of $102.6 million for the first quarter of 2021, up 66% compared to net revenue of $61.7 million for...

Reports Revenue Growth of 58% and Positive Adjusted EBITDA* NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) — Acreage Holdings, Inc. (“Acreage”) (CSE: ACRG.A.U, ACRG.B.U), (OTC: ACRHF, ACRDF) a multi-state operator of cannabis ‎cultivation and retailing facilities in the U.S., today reported financial results for the first quarter of 2021. FIRST QUARTER RESULTS (UNAUDITED) During the first quarter of 2021, Acreage continued to improve its financial performance and made progress against its strategic initiatives. Highlights for the quarter are summarized below.Consolidated revenue was $38.4 million, a 58% increase compared to the same period in 2020 and a sequential increase of 22% compared to the fourth quarter of 2020. Company-owned same store sales growth was 16%, marking the ninth consecutive quarter of double-digit same store sales...

TORONTO, May 10, 2021 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”), a global leader in cannabis wellness products and services, is pleased to announce that CEO Geoffrey Benic will present at Canaccord Genuity’s Global Cannabis Conference on Tuesday, May 11, 2021 at 11:00 a.m. EDT. Participants can access the webcast through this link, with a replay expected to be made available shortly after the conclusion of the presentation. For Investor & Media Relations: Nicholas Bergamini, VP Investor Relations1-833-879-2533IR@AleafiaHealth.comLEARN MORE: www.AleafiaHealth.com About Aleafia Health: Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and in international markets....

NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) — VORNADO REALTY TRUST (NYSE: VNO) announced today that it has completed a $1.2 billion refinancing of 555 California Street, a three building 1.8 million square foot trophy office campus in San Francisco. The interest only loan bears a rate of LIBOR plus 1.93% in years one through five, LIBOR plus 2.18% in year six and LIBOR plus 2.43% in year seven. The loan matures in May 2028, as fully extended. Vornado swapped its share of the loan for the first three years to a fixed rate of 2.26%. The loan replaces the previous $533 million loan that bore interest at a fixed rate of 5.10% and was scheduled to mature in September 2021. Vornado’s share of the net proceeds was approximately $454 million. Vornado owns a 70% controlling interest in the partnership that owns the buildings and has sole decision-making...